Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 7Neoplasms 5Melanoma 3Warts 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hyperthermia 2Hematologic Neoplasms 2Hemangioma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tuberous Sclerosis 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Seizures 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pelvic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Nonmelanoma Skin Cancers 1Mucositis 1

Interventions

Solutions 1Haloperidol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Haloperidol × Solutions × Clear all
NCT04833023 2024-04-12

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Tan Tock Seng Hospital

Phase 3 Unknown
72 enrolled

Haloperidol

Data powered by HemOnc (CC BY 4.0) Colophon âš¡